The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Fullerenol−Cytotoxic Conjugates for Cancer Chemotherapy
Abstract
In the present study, we report the novel application of polyhydroxylated fullerenes (fullerenols) in cancer drug delivery. The facile synthetic procedure for generating multiple hydroxyl groups on the fullerene cage offers scope for high drug loading in addition to conferring hydrophilicity. Doxorubicin, a first line cancer chemotherapeutic, was conjugated to fullerenols through a carbamate linker, achieving ultrahigh loading efficiency. The drug-fullerenol conjugate was found to be relatively stable in phosphate buffer saline but temporally released the active drug when incubated with tumor cell lysate. The fullerenol-doxorubicin conjugate suppressed the proliferation of cancer cell-lines in vitro through a G2-M cell cycle block, resulting in apoptosis. Furthermore, in an in vivo murine tumor model, fullerenol-doxorubicin exhibited comparable antitumor efficacy as free drug without the systemic toxicity of free doxorubicin. Additionally, we demonstrate that the fullerenol platform can be extended to other chemotherapeutic agents, such as the slightly water-soluble cisplatin, and can emerge as a new paradigm in the management of cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Cancer nanotechnology: opportunities and challenges
Ferrari, M. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1566 · Cited by 4,558
Cited by
Cancer Nanomedicine: From Drug Delivery to Imaging
Chow, E. K.-H., & Ho, D. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005872 · Cited by 491
Diverse gatekeepers for mesoporous silica nanoparticle based drug delivery systems
Wen, J., Yang, K., Liu, F., Li, H., Xu, Y., & Sun, S. (2017) · Chemical Society Reviews · doi:10.1039/c7cs00219j · Cited by 477
Eivazzadeh-Keihan, R., Maleki, A., de la Guardia, M., Bani, M. S., Chenab, K. K., Pashazadeh-Panahi, P., Baradaran, B., Mokhtarzadeh, A., & Hamblin, M. R. (2019) · Journal of Advanced Research · doi:10.1016/j.jare.2019.03.011 · Cited by 389
Fullerene: biomedical engineers get to revisit an old friend
Goodarzi, S., Da Ros, T., Conde, J., Sefat, F., & Mozafari, M. (2017) · Materials Today · doi:10.1016/j.mattod.2017.03.017 · Cited by 368
Effect of Nanoparticles on the Cell Life Cycle
Mahmoudi, M., Azadmanesh, K., Shokrgozar, M. A., Journeay, W. S., & Laurent, S. (2011) · Chemical Reviews · doi:10.1021/cr1003166 · Cited by 352
Metadata
- Authors
- Chaudhuri, P., Paraskar, A., Soni, S., Mashelkar, R. A., & Sengupta, S.
- Venue
- ACS Nano
- Publisher
- American Chemical Society (ACS)
- Published
- 2009-08-14
- Volume
- 3
- Issue
- 9
- Pages
- 2505-2514
- ISSN
- 1936-0851 (ISSN-L)
- 1936-086X
- OpenAlex
- W2063824519
- Cited by
- 228
- References
- 2
- FWCI
- 7.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.